Explore the Agenda
8:30 am Check-In & Coffee + Light Breakfast
9:15 am Chair’s Opening Remarks
Expanding Biologic Innovation to Broaden the Reach of Druggable Targets
9:30 am Discovery of GPCR Agonist Antibodies Using the FAST Platform
- Abalone Bio’s Functional Antibody Selection Technology (FAST) platform measures antibody activity at scale, not just binding, enabling the discovery and design of agonist antibodies for GPCRs
- The large-scale sequence-function datasets generated uniquely power AI/ML models to identify novel active antibody sequences
- Using FAST, we have identified diverse agonists against five GPCRs, 3/3 with in vivo activity
10:00 am Presentation Details to be Announced
10:30 am Targeting Intrinsically Disordered GPCR Regions to Unlock New Opportunities for Selective Therapeutic Design
- Leveraging structural and computational approaches to characterize intrinsically disordered regions that regulate GPCR signaling and selectivity
- Exploring antibody-based strategies to target receptor-specific intracellular regulatory elements across orphan and disease-relevant GPCRs
- Establishing new approaches to improve therapeutic selectivity by modulating GPCR function beyond traditional extracellular binding sites
11:00 am Morning Break & Networking
Forecasting Opportunities Beyond GLP-1 to Capture the Next Wave of Therapeutic Innovation
11:30 am Fireside Chat: Beyond GLP-1 – Where Will the Next GPCR Success Story Come From?
- Beyond metabolic disease, where do pharma see the greatest unmet need and commercial opportunity across the GPCR landscape?
- Does success in this space require replicating GLP-1’s model, or can differentiated mechanisms in entirely different indications define the field’s next major win?
- What is the industry actually looking for right now when evaluating a new GPCR program, and how does that differ from what got funded or partnered five years ago?
12:00 pm Applying Iterative Machine Learning to Expand GPCR Therapeutics Beyond GLP-1
- Demonstrating how internally generated biological data can continuously improve GPCR prediction performance across successive discovery campaigns
- Transferring learnings from GLP-1-focused programs to accelerate discovery against novel intestinal GPCR targets
- Advancing next-generation peptide therapeutics for muscle preservation, metabolic health and post-GLP-1 patient support through AI-enabled discovery
12:30 pm Networking Lunch
Transforming Metabolic & Endocrine Disease Outcomes Through Differentiated Therapeutics
1:30 pm The Discovery & Development of ATR-258, a GRK2-Biased β2AR Agonist for the Treatment of Metabolic Disorders
- Advancing ATR-258 from early discovery into Phase 2 clinical development
- From Type 2 Diabetes and obesity to muscle-preserving weight loss and functional health
- Molecular dynamics calculations reveal a hitherto undescribed β2AR conformation
2:00 pm Advancing a First-in-Class SSTR5 Agonist Antibody for Post-Bariatric Hypoglycemia
- Progressing Confo’s lead SSTR5 agonist antibody from discovery through candidate nomination and IND-enabling studies
- Demonstrating how selective GPCR agonist antibodies can restore glycemic control in post-bariatric hypoglycemia through targeted modulation of insulin and incretin signaling
- Sharing scientific and translational learnings from advancing one of the field’s most advanced GPCR agonist antibody programs toward clinical development
2:30 pm Afternoon Break & Networking
Applying Precision Immunology to Deliver More Effective Oncology & Inflammatory Disease Therapies
3:00 pm Engineering Functional CCR8 Antibodies to Advance Differentiated Immuno-Oncology Therapies
- Demonstrating how functional characterization can identify GPCR-targeting antibodies with differentiated biological activity
- Leveraging translational biomarker strategies to validate target engagement and support clinical development
- Showcasing the development of a CCR8-targeting antibody program designed to overcome immunosuppressive mechanisms in solid tumors
3:30 pm Translating Chemotaxis Biology into Development-Ready GPCR Therapeutics for Autoimmune Disease
- Leveraging chemotaxis biology to identify GPCR targets capable of delivering more precise immune modulation in autoimmune disease
- Applying modern pharmacology and translational strategies to optimize target coverage, exposure and candidate quality before entering the clinic
- Sharing lessons learned from advancing a GPCR therapeutic through IND-enabling development